Opportunity ID: 317917

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-19-306
Funding Opportunity Title: FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Agriculture
Consumer Protection
Food and Nutrition
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.103 — Food and Drug Administration Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Jul 02, 2019
Last Updated Date: Jul 02, 2019
Original Closing Date for Applications: Oct 11, 2022
Current Closing Date for Applications: Oct 11, 2022
Archive Date: Nov 10, 2022
Estimated Total Program Funding:
Award Ceiling: $250,000
Award Floor:

Eligibility

Eligible Applicants: State governments
County governments
Small businesses
For profit organizations other than small businesses
Special district governments
Native American tribal organizations (other than Federally recognized tribal governments)
Private institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal governments (Federally recognized)
City or township governments
Independent school districts
Public housing authorities/Indian housing authorities
Public and State controlled institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility:

Additional Information

Agency Name: Food and Drug Administration
Description:

    The FDA recognizes the value of supporting high quality conferences and scientific meetings relevant to its mission and to the public health. A conference or scientific meeting is defined as a symposium, seminar, workshop, or any formal meeting, whether conducted face-to-face or virtually to exchange information and explore a defined subject, issue, or area of concern impacting the public’s health within the scope of the FDA’s mission. Support of such meetings is contingent upon the

    fiscal and programmatic interests and priorities of the FDA’s respective Offices and Centers.

    Therefore, a conference grant application is required to contain an advance permission-to-submit letter from one of the participating FDA Centers listed under Components of Participating Organizations.

    Advanced Permission to Submit an Application:

    A Letter of Intent requesting advanced permission to submit a conference application is required and must be received via e-mail no later than eight (8) weeks prior to the selected application due date.

    To request advanced permission to submit an application letter from one of the participating FDA Centers/Offices, applicants must submit the following information on applicant organizational letterhead:

    • FOA Number and Title;
    • Selected application due date;
    • FDA Center/Office that the application is seeking advanced permission to apply to; 
    • Meeting/conference title;
    • Location and date of proposed meeting/conference;
    • Names, Address, Telephone number and email address of Institution(s) participating in the application;
    • Name, Address, Telephone number and email address of the Principal Investigator/Project Director;
    • Names of other key personnel (if any) and points of contact;
    • Number of anticipated attendees;
    • Purpose, benefit, objectives and/or justification of the meeting/conference and how it aligns with the mission and program priorities of the targeted FDA Center/Office;
    • Estimated budget that will be requested for the meeting/conference and purpose; and
    • List other sources of funding (secured and planned), if applicable.

    All advanced permission to submit an application requests must be submitted via email to the Grants Management Contact listed in Section VII. Agency Contacts of this FOA.  Applicants are urged to initiate contact well in advance of the chosen application due date and no later than 8 weeks before that date. Advanced permission to submit an application requests received after 8 weeks prior to the selected application due date will not be accepted. Please note that agreement to accept an application does not guarantee funding or funding at the level requested. 

    Consistent with Federal civil rights laws, it is expected that organizers of FDA-supported conferences and scientific meetings take steps to maintain a safe and respectful environment for all attendees by providing an environment free from discrimination and harassment, sexual or otherwise.  

Link to Additional Information: Funding Opportunity Announcement
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

Kiara Fowler

Grants Management Specialist

Phone 2404023099
Email:kiara.fowler@fda.hhs.gov

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: Kiara Fowler
Grants Management Specialist
Phone 2404023099
Email: kiara.fowler@fda.hhs.gov
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
93.103 PAR-19-306 FORMS-F Use for due dates on or after May 25, 2020 PKG00252528 Jul 02, 2019 Nov 13, 2021 View
93.103 PAR-19-306-FORMS-G FORMS G – For due dates on or after January 25, 2022 PKG00270062 Nov 12, 2021 Oct 11, 2022 View

Package 1

Mandatory forms

317917 RR_SF424_2_0-2.0.pdf

317917 PHS398_CoverPageSupplement_5_0-5.0.pdf

317917 RR_OtherProjectInfo_1_4-1.4.pdf

317917 PerformanceSite_2_0-2.0.pdf

317917 RR_KeyPersonExpanded_2_0-2.0.pdf

317917 RR_Budget_1_4-1.4.pdf

317917 PHS398_ResearchPlan_4_0-4.0.pdf

317917 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf

Optional forms

317917 RR_SubawardBudget30_1_4-1.4.pdf

317917 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 2

Mandatory forms

317917 RR_SF424_5_0-5.0.pdf

317917 PHS398_CoverPageSupplement_5_0-5.0.pdf

317917 RR_OtherProjectInfo_1_4-1.4.pdf

317917 PerformanceSite_4_0-4.0.pdf

317917 RR_KeyPersonExpanded_4_0-4.0.pdf

317917 RR_Budget_3_0-3.0.pdf

317917 PHS398_ResearchPlan_4_0-4.0.pdf

317917 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

317917 RR_SubawardBudget30_3_0-3.0.pdf

317917 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-09T20:16:14-05:00

Share This Post, Choose Your Platform!

About the Author: